Biogen and Eisai reported the finding from a large late-stage clinical trial of lecanemab, a drug they are developing.
Tag: Biogen Inc
-
Biogen Agrees to Pay $900 Million to Settle Lawsuit Over Kickbacks
The company was accused of illegally paying doctors to prescribe its drugs over those of its rivals.
-
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.
-
In India, Parents of Children with Rare Disease Plea for Help Online
India makes many of the world’s drugs, but treatments for rare diseases like spinal muscular atrophy are imported and prohibitively costly. In desperation, parents are raising funds on social media.
-
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drug
The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.